Sun Pharmaceutical Industries Ltd. News and Updates

Name: Latest research reports of Sun Pharmaceutical Industries Ltd. authored by Karvy and published by - Trendlyne research reports.
Item: Sun Pharmaceutical Industries Ltd.
Rating: 3
Author: Karvy

Keep track of all breaking news on Sun Pharmaceutical Industries Ltd. from all sources in a single place.

Load latest

Sun Pharmaceutical Industries Ltd.

10 Feb 2020

1593.60

0.71%

Sun Pharmaceutical Industries Ltd: Pharmaceuticals

Hold: Sun Pharmaceutical Industr...

Target

Karvy

India and ROW Markets OutperformNet Revenues for the quarter increased by 5.4% YoY to Rs. 81.5 bn.

Sun Pharmaceutical Industries Ltd. is trading below all available SMAs

Sun Pharmaceutical Industries Ltd.

09 Feb 2020

1593.60

0.71%

Sun Pharma: India picks up slack inQ3,specialty drug ramp-up key

livemint

Sun Pharma is expanding its field force by 10%, most of whom may join by Q1 of FY21. This strategy is in line with other drug makers.To overcome the pricing pressure, Sun Pharma is building specialty products, which are difficult to develop and imitate

Sun Pharmaceutical I.. has an average target of 2050.25 from 8 brokers.

Sun Pharmaceutical Industries Ltd.

07 Feb 2020

1593.60

0.71%

Sun Pharma share price gains 2.41% despite weak Q3 numbers; here's what brokerages say

Business Today

Following the earnings announcement, share price of Sun Pharmaceutical hit the intraday high of Rs 441 on Friday, rising 2.47% as against the previous closing price of Rs 430.95.

Sun Pharmaceutical Industries Ltd. is trading below all available SMAs

Sun Pharma Consolidated December 2019 Net Sales at Rs 8,154.85 crore, up 5.36% Y-o-Y

Moneycontrol | 07 Feb 2020 5 more

Sun Pharmaceutical Industries Ltd.

07 Feb 2020

1593.60

0.71%

Sun Pharma (Update): Specialty scale up holds promise. BUY

Buy: Sun Pharmaceutical Industr...

Target

HDFC Securities

Key downside risks: slower ramp up in Ilumya, higher price erosion in the US, lower growth in the India, adverse outcome on SEBI's probe on whistle-blower complaint, drug price fixing lawsuits in the US. We resume coverage on Sun Pharma with a Buy rating and TP of Rs 500 based on 22x FY22 EPS. Suns business outlook for the next two years will be driven by ramp up in specialty portfolio led by Illumya and Cequa. We expect the improved traction in specialty sales will drive operating leverage and aid margin expansion. This, along with healthy growth in India and EM markets will drive 14% earnings CAGR over FY20-22e. The stock trades at attractive valuation of 19x FY22 EPS , ~10% discount to its 5-year average PER.

Sun Pharmaceutical Industries Ltd. is trading below all available SMAs

Sun Pharmaceutical Industries Ltd.

07 Feb 2020

1593.60

0.71%

Sun Pharma

Hold: Sun Pharmaceutical Industr...

Target

ICICI Securities Limited

Indraprastha Gas (IGL) reported its Q3FY20 numbers that were marginally above our estimates on account of higher-than-expected volumes as well as margins. Volumes increased 13.4% YoY to 6.7 mmscmd and came in marginally above our estimate of 6.6 mmscmd. Revenues increased 10.3% YoY to | 1664.2 crore, in line with our estimate of | 1674.5 crore. EBITDA increased 23.3% YoY to | 391.8 crore (our estimates: | 376.7 crore) on lower than estimated gas costs. Subsequently, PAT came in at | 283.9 crore (up...

Sun Pharmaceutical I.. has an average target of 2050.25 from 8 brokers.

Sun Pharmaceutical Industries Ltd.

07 Feb 2020

1593.60

0.71%

Sun Pharma (REDUCE): Q3 a tad lower US (ex-Taro) ramp-up subdued; REDUCE

Sell: Sun Pharmaceutical Industr...

Target

BOB Capital Markets Ltd.

Sun Pharma (SUNP) reported a 6% EBITDA miss, largely driven by higher other expense (up 8% QoQ) and despite better gross margins (up 110bps QoQ) & lower R&D; (6.4% of sales).

Number of FII/FPI investors decreased from 1351 to 1326 in Jun 2025 qtr

Sun Pharmaceutical Industries Ltd.

06 Feb 2020

1593.60

0.71%

Better performance in India/ROW offset by EM/US

Buy: Sun Pharmaceutical Industr...

Target

Motilal Oswal

6 February 2020 SUNP gradually enhanced traction in its specialty portfolio with some support of seasonality in the quarter. We believe that RoE at 9% has bottomed out in FY19 and would revive on the back of increased traction in the specialty portfolio, new launches in US generics and in-line industry growth in the DF segment. Maintain 3QFY20 sales were up 5% YoY to INR80.4b (in-line), led by India sales growth of 18% YoY to INR74b (31% of sales) and RoW sales growth of 24% YoY to USD155m (14% of sales). US sales (31% of total sales) were down 3% YoY and continue to face competition heat affecting overall growth at USD350m. Taro posted 3QFY20 sales of USD148m, down 16% YoY. Emerging market sales at USD195m (17% of sales) were down 4% YoY. Gross margin for the quarter came in at 72.6% (+90bp YoY, +120bp QoQ).

Number of FII/FPI investors decreased from 1351 to 1326 in Jun 2025 qtr

Sun Pharmaceutical Industries Ltd.

04 Feb 2020, 08:24PM

1593.60

0.71%

Sun Pharma launches severe nodular acne management capsules in US

Moneycontrol

The product launched by company's wholly owned subsidiaries for the management of severe recalcitrant nodular acne in patients of 12 years of age and older, it can be taken with or without food, Sun Pharma said in a filing to BSE.

Number of FII/FPI investors decreased from 1351 to 1326 in Jun 2025 qtr

Sun Pharmaceutical Industries Ltd.

04 Feb 2020, 12:52PM

1593.60

0.71%

Sun Pharma share price slips 1% on weak Q3 show by US subsidiary

Moneycontrol

Operating income shed 26.3 percent at USD 58.19 million and operating margin was at 39.4 percent versus 44.7 percent, YoY.

Sun Pharmaceutical I.. has an average target of 2050.25 from 8 brokers.

Sun Pharmaceutical Industries Ltd.

04 Feb 2020, 12:00AM

1593.60

0.71%

Event Update

Sell: Sun Pharmaceutical Industr...

Prabhudas Lilladhar

Taro had weakest sales in 22 quarters with 16% YoY (and 8% QoQ) decline to US$148m in Q3FY20. Higher intensity of competitive pricing and lack of volume growth in derma portfolio were key reasons for strong erosion in sales. Gross profit was US$94m, declined by 20% YoY and 8% QoQ, while gross margin was 63.7% compared to 66.6% in Q3FY19 and 63.1% in Q2FY20. EBITDA declined by 24% YoY (and 14% QoQ) to $63.6mn, while EBITDA...